| Patent application number | Description | Published |
|---|
| 20100063783 | SYSTEMS AND METHODS FOR MODELING OF CRYSTALLIZATION PROCESSES - A computer system and method of modeling a crystallization process includes representing a plurality of crystals in a solution by different subsets of the plurality, tracking increase of the respective characteristic length of each crystal group, and determining a crystal size distribution to output a model to a user. Ech subset forms a respective crystal group characterized by group attributes of (i) a number of crystals and (ii) a characteristic length. Additionally, the system and method track generation of new crystal groups generated by seeding, nucleation and/or breakage. | 03-11-2010 |
| 20100114542 | Methods of modeling physical properties of chemical mixtures and articles of use - Included are methods for modeling at least one physical property of a mixture of at least two chemical species. One or more chemical species of the mixture are approximated or represented by at least one conceptual segment. The conceptual segments are then used to compute at least one physical property of the mixture. An analysis of the computed physical properties forms a model of at least one physical property of the mixture. Also included are computer program products and computer systems for implementing the modeling methods. | 05-06-2010 |
| 20100280810 | System and Method of Modeling Mono-Glycerides, Diglycerides and Triglycerides in Biodiesel Feedstock - A computer-implemented method and system of modeling physical properties of biodiesel feedstock are presented. The invention method and system include (i) estimating values of a physical property of constituent fatty acid fragments of a mono-, di-, or triglyceride, and (ii) computing a value of the physical property of the mono-, di-, or triglyceride by expressing the value of the physical property of the mono-, di-, or triglyceride as a sum of the estimated values of the physical property of constituent fatty acid fragments thereof. The method and system further include repeating steps (i) and (ii) for different mono-, di-, and/or triglycerides, resulting in a plurality of computed values of the physical property of different mono-, di-, and triglycerides. Using the resulting plurality, the method and system determine a value of a subject physical property of a biodiesel feedstock by expressing the value of the subject physical property of the biodiesel feedstock as a sum of values from the resulting plurality of the computed mono-, di-, and triglyceride physical property values corresponding to constituent mono-, di-, and triglycerides of the biodiesel feedstock. The determined value of the subject physical property enables blending of the biodiesel feedstock in production of biodiesel. | 11-04-2010 |
| 20110046936 | COMPUTER METHOD AND SYSTEM FOR PREDICTING PHYSICAL PROPERTIES USING A CONCEPTUAL SEGMENT-BASED IONIC ACTIVITY COEFFICIENT MODEL - In the present invention the NonRandom Two-Liquid segment activity coefficient model system of the parent application is extended for computation of ionic activity coefficients and solubilities of electrolytes, organic and inorganic, in common solvents and solvent mixtures. The invention method and system may be applied to the chemical and/or pharmaceutical design process. In addition to the three types of molecular parameters defined for organic nonelectrolytes, i.e., hydrophobicity X, polarity Y, and hydrophilicity Z, an electrolyte parameter, E, is introduced to characterize both local and long-range ion-ion and ion-molecule interactions attributed to ionized segments of electrolytes. Successful representations of mean ionic activity coefficients and solubilities of electrolytes, inorganic and organic, in aqueous and nonaqueous solvents are presented. | 02-24-2011 |
| Patent application number | Description | Published |
|---|
| 20080226730 | PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. | 09-18-2008 |
| 20080227690 | PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. | 09-18-2008 |
| 20080253971 | Particles for inhalation having sustained release properties - The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. | 10-16-2008 |
| 20110077284 | DRY POWDER COMPOSITIONS FOR RNA INFLUENZA THERAPEUTICS - A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of a dry powder formulation. | 03-31-2011 |
| Patent application number | Description | Published |
|---|
| 20090081249 | Bi-Functional Polymer-Attached Inhibitors of Influenza Virus - Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration. Suitable oral/intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance. | 03-26-2009 |
| 20090106852 | Influenza Therapeutic - The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza. | 04-23-2009 |
| 20090124567 | Influenza Therapeutic - The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza. | 05-14-2009 |
| 20100298214 | TREATMENT OF AUTOIMMUNE DISEASE - The present invention provides compositions, systems, and methods for identifying a patient suffering from and/or susceptible to autoimmune disease who might be likely to respond to treatment with CXCL12 and/or CXCR4 antagonists. The present invention provides novel CXCL12 and/or CXCR4 antagonists, methods of identifying novel CXCL12 and/or CXCR4 antagonists, and methods involving the use of these in the treatment of autoimmune disease. | 11-25-2010 |
| 20110112169 | RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA - The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route. | 05-12-2011 |
| Patent application number | Description | Published |
|---|
| 20090107722 | MORPHIBLE BIT - According to the invention, a bottom hole assembly for drilling a cavity is disclosed. The bottom hole assembly may include a chassis configured to rotate. The chassis may include a primary fluid conduit, a secondary fluid circuit, a pressure transfer device, a plurality of pistons, a plurality of valves, and a plurality of cutters. The primary fluid conduit may be accept a first fluid flow. The secondary fluid circuit may have a second fluid flow. The pressure transfer device may be configured to transfer pressure between the flows. The pistons may be operably coupled with the secondary fluid circuit, and each piston may be configured to move based at least in part on a pressure of the secondary fluid circuit at that piston, with the valves possibly configured to control a pressure of the secondary fluid circuit at each piston. Each cutter may be coupled with one of the pistons. | 04-30-2009 |
| 20090134631 | HARVESTING ENERGY IN REMOTE LOCATIONS - Electrical energy is produced at a remote site by converting kinetic energy from the environment. The kinetic energy may include vibrations and flow of fluid. In some embodiments the kinetic energy causes magnets to move with respect to coils in order to produce electrical energy. An anchor holds the device in place, and permits the device to be retrieved or relocated. A flexure or compliant membrane that helps determine the position of the magnets with respect to coils is defined by mechanical properties that permit oscillatory movement in response to the inputted kinetic energy. The device can be tuned to different vibration and flow regimes in order to enhance energy conversion efficiency. Further, the device may be mounted in a secondary flow path such as a side package or annular tube. | 05-28-2009 |
| 20090140604 | HARVESTING ENERGY FROM FLOWING FLUID - Electrical energy is produced at a remote or close site by converting kinetic energy from fluid flow with membranes that generates electrical energy in response to deformation by the fluid flow passing though a piezo electric medium attached to the deforming membranes. Sets of membranes define variable fluid flow restrictors that oscillate due to interaction of the force of fluid flow and Bernoulli Effect. The device can be tuned to different flow regimes in order to enhance energy conversion efficiency. Each membrane may include one or more layers of piezoelectric material separated by insulating/stiffening layers. Further, the device may be mounted in a secondary flow path such as a side package or annular tube. | 06-04-2009 |
| 20090230335 | TEMPERATURE TRIGGERED ACTUATOR - An actuator is disclosed which operates on the principle of the variable magnetic properties of materials with respect to temperature. As temperature is raised past Curie temperature, magnetic permeability of certain materials drops significantly to a value close to free space permeability. However, depending on the material selection, magnetic permeability may be significantly higher below Curie temperature. This principle is used to cause magnetic attractive force to move an actuator at one temperature, while permitting a return spring force to move the actuator at another temperature by changing the pathway traversed by most magnetic lines of flux from a magnetic source. The actuator may be employed to provide a temperature activated electrical switch or fluid valve. The temperature activated valves are suited to use in high temperature environments, such as SAGD wells. | 09-17-2009 |
